Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

matt liddelow

  • Home
  •  
  • matt liddelow



  • Most Read
  • Latest Comments
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Following HREC rejection, NeuroScientific Biopharma bounces back with new patent for EmtinB to treat multiple sclerosis
    Following HREC rejection, NeuroScientific Biopharma bounces back with new patent for EmtinB to treat multiple sclerosis
    • News

  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

  • Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke
    Unethical human trials, NeuroScientific Biopharmaceuticals rejected by regulator with years of research up in smoke
    • News

  • Paradigm’s study could give options to those with this rare incurable disease
    Paradigm’s study could give options to those with this rare incurable disease
    • News

  • Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    • News

  • Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee
    • News

    Neuroscientific Biopharmaceuticals CEO resigns as years of research snubbed by ethics committee

    After the Human Research Ethics Committee (HREC) rejected the Company’s flagship drug, EmtinB, knocking back years of research in the process, disappointed CEO and Managing Director, Mr Matt Liddelow, announced that he is resigning from his position immediately.  Liddelow noted, “I acknowledge the loss in shareholder value as a result of the rejected Human Research

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.